Autres langues GenSight Biologics S.A.

Actions

SIGHT

FR0013183985

Marché Fermé - Euronext Paris Autres places de cotation 17:35:19 30/04/2024			Après clotûre 19:53:50
0,395 ^EUR	-3,66%		0,395	0,00%

05/04	GenSight : visibilité financière assurée jusqu'à fin avril	CF
05/04	GenSight Biologics S A : veut prolonger sa visibilité au-delà d'avril 2024	AO

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

GenSight Biologics S A : Inside Information / News release on accounts, results	18/04
GenSight Biologics Announces the Filing of its 2023 Universal Registration Document	18/04
GenSight Biologics S A : Announces the Filing of its 2023 Universal Registration Document	17/04
GenSight : visibilité financière assurée jusqu'à fin avril	05/04
GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update	04/04
GenSight Biologics Announces its 2024 Financial Calendar	04/04
GenSight Biologics S A : Reports Cash Position as of March 31, 2024, and Provides Business Update	04/04
GenSight Biologics S A : Announces Its 2024 Financial Calendar	04/04
GenSight : le titre chute, visibilité financière limitée	25/03
GenSight Biologics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03
GenSight Biologics Reports Full Year 2023 Consolidated Financial Results	22/03
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration	20/03
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ®? Injections Four Years After One-Time Administration	20/03
GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ Gene Therapy at NANOS 2024	13/03
GenSight Biologics : résultat sur la thérapie génique Lumevoq	12/03
GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024	12/03
GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024	12/03
GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ Gene Therapy at NANOS 2024	07/03
EN DIRECTO DESDE LOS MERCADOS: Indra, Acciona, Sabadell, Unicaja, Bankinter, BBVA, Cellnex , DHL, Temenos ...	06/03
GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024	06/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues GenSight Biologics S.A.

Actions

SIGHT

FR0013183985

Autres langues

Filtres